Bristol Myers gets necessary clearance for $4.1B Turning Point acquisition
After a brief delay, Bristol Myers Squibb is finally about to close on its $4.1 billion Turning Point acquisition.
BMS announced on Tuesday that it has received merger control clearance from the Federal Cartel Office of Germany, and expects to close on the deal tomorrow. The pharma giant struck a deal earlier this summer to snatch up all outstanding Turning Point shares for $76 apiece, or a total of $4.1 billion. Turning Point’s stock $TPTX more than doubled on the news back in June, and has remained practically level since.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.